新型冠状病毒(2019-nCoV)疫情正在迅速向全球蔓延。截止2020年3月6日,全球累计98373人, 累计死亡3388人。由于目前没有特效药可以治疗新冠肺炎,治疗新冠肺炎的药物研发迫在眉睫。通过以AI为架构的药物筛选手段,可以发现多种可能对2019-nCoV有治疗作用的药物及化合物。阿拉丁提供以下几十款试剂作为此药物研发的研发用材料。
韩国Deargen公司、美国佐治亚州亚特兰大市埃默里大学、韩国天安市担国大学自然科学学院联,利用药物-靶点相互作用模型(MT-DTI),预测了与新型冠状病毒(2019-nCoV) 3C样蛋白酶、RNA依赖RNA聚合酶、解旋酶、3 '- 5 '核酸外切酶、内切RNA酶、内切RNA酶的药物及化合物。

抑制新型冠状病毒(2019-nCoV) 3C样蛋白酶的DTI预测结果
项目号 |
产品名称 |
纯度 |
CAS |
规格 |
A125825 |
Atazanavir
阿扎那韦 |
- |
198904-31-3 |
10mg,50mg,250mg,5g |
E135556 |
Efavirenz
依法韦仑 |
≥98%(HPLC) |
154598-52-4 |
10mg,50mg,250mg,1g,5g |
R126586 |
利托那韦
Ritonavir |
≥98% |
155213-67-5 |
10mg,50mg,250mg,500mg |
D127636 |
多替拉韦
Dolutegravir |
≥99% |
1051375-16-6 |
5mg,10mg,50mg |
A126103 |
Asunaprevir
阿那匹韦 |
≥98% |
630420-16-5 |
5mg,10mg,50mg,250mg |
S127117 |
Simeprevir
西咪匹韦 |
≥99% |
923604-59-5 |
5mg,10mg,50mg,100mg |
抑制新型冠状病毒(2019-nCoV)的RNA依赖RNA聚合酶的DTI预测结果
项目号 |
产品名称 |
纯度 |
CAS |
规格 |
M124903 |
MK-5172 |
98% |
1350514-68-9 |
5mg,10mg |
G129109 |
Ganciclovir
更昔洛韦 |
≥98.0% |
82410-32-0 |
1g,5g,25g,100g |
A125825 |
Atazanavir
阿扎那韦 |
- |
198904-31-3 |
10mg,50mg,250mg,5g |
D127186 |
Daclatasvir(BMS-790052) |
≥98% |
1009119-64-5 |
10mg,50mg,250mg |
E126710 |
Etravirine (TMC125) |
≥95% |
269055-15-4 |
5mg,25mg,100mg,1g |
E181466 |
Entecavir
恩替卡韦 |
98% |
142217-69-4 |
250mg,1g |
E135556 |
Efavirenz
依法韦仑 |
≥98%(HPLC) |
154598-52-4 |
10mg,50mg,250mg,1g,5g |
A126103 |
Asunaprevir
阿那匹韦 |
≥98% |
630420-16-5 |
5mg,10mg,50mg,250mg |
A126552 |
Abacavir
阿巴卡韦 |
≥98.0% |
136470-78-5 |
1g,5g |
D127636 |
多替拉韦
Dolutegravir |
≥99% |
1051375-16-6 |
5mg,10mg,50mg |
V127611 |
VX-222 (VCH-222, Lomibuvir) |
≥99% |
1026785-59-0 |
5mg,10mg,50mg |
P125160 |
Penciclovir
喷昔洛韦 |
≥99% |
39809-25-1 |
50mg,250mg,1g |
D127014 |
Danoprevir (ITMN-191) |
≥95% |
850876-88-9 |
2mg,5mg,25mg |
R126586 |
利托那韦
Ritonavir |
≥98% |
155213-67-5 |
10mg,50mg,250mg,500mg |
S126514 |
沙奎那韦
Saquinavir |
≥98% |
127779-20-8 |
25mg,100mg |
R129802 |
Raltegravir(MK-0518) |
≥97% |
518048-05-0 |
5mg,10mg,50mg,1g |
抑制新型冠状病毒(2019-nCoV)的解旋酶的DTI预测结果
项目号 |
中文名称 |
规格 |
CAS |
包装 |
S127117 |
Simeprevir
西咪匹韦 |
≥99% |
923604-59-5 |
5mg,10mg,50mg,100mg |
A125825 |
Atazanavir
阿扎那韦 |
- |
198904-31-3 |
10mg,50mg,250mg,5g |
M124903 |
MK-5172 |
98% |
1350514-68-9 |
5mg,10mg |
A126103 |
Asunaprevir
阿那匹韦 |
≥98% |
630420-16-5 |
5mg,10mg,50mg,250mg |
T126775 |
Telaprevir
特拉匹韦 |
≥98% |
402957-28-2 |
5mg,10mg,50mg |
R126586 |
利托那韦
Ritonavir |
≥98% |
155213-67-5 |
10mg,50mg,250mg,500mg |
L299096 |
洛比那韦
Lopinavir |
95% |
192725-17-0 |
10mg,50mg,250mg,1g |
L129320 |
洛比那韦
Lopinavir |
≥99% |
192725-17-0 |
10mg,50mg,100mg,250mg,1g |
D125841 |
达芦那韦
Darunavir |
98% |
206361-99-1 |
5mg,10mg,50mg,250mg,1g |
G129109 |
Ganciclovir
更昔洛韦 |
≥98.0% |
82410-32-0 |
1g,5g,25g,100g |
P125160 |
Penciclovir
喷昔洛韦 |
≥99% |
39809-25-1 |
50mg,250mg,1g |
E126710 |
Etravirine (TMC125) |
≥95% |
269055-15-4 |
5mg,25mg,100mg,1g |
R129802 |
Raltegravir(MK-0518) |
≥97% |
518048-05-0 |
5mg,10mg,50mg,1g |
D127636 |
多替拉韦
Dolutegravir |
≥99% |
1051375-16-6 |
5mg,10mg,50mg |
N137745 |
奈非那韦
Nelfinavir Mesylate |
98% |
159989-65-8 |
10mg,50mg,250mg |
E135556 |
Efavirenz
依法韦仑 |
≥98%(HPLC) |
154598-52-4 |
10mg,50mg,250mg,1g,5g |
E181466 |
Entecavir
恩替卡韦 |
98% |
142217-69-4 |
250mg,1g |
R126586 |
利托那韦
Ritonavir |
≥98% |
155213-67-5 |
10mg,50mg,250mg,500mg |
V127611 |
VX-222 (VCH-222, Lomibuvir) |
≥99% |
1026785-59-0 |
5mg,10mg,50mg |
抑制新型冠状病毒(2019-nCoV)的3 '- 5 '核酸外切酶的DTI预测结果
项目号 |
中文名称 |
规格 |
CAS |
包装 |
S127117 |
Simeprevir
西咪匹韦 |
≥99% |
923604-59-5 |
5mg,10mg,50mg,100mg |
E135556 |
Efavirenz
依法韦仑 |
≥98%(HPLC) |
154598-52-4 |
10mg,50mg,250mg,1g,5g |
D127014 |
Danoprevir (ITMN-191) |
≥95% |
850876-88-9 |
2mg,5mg,25mg |
G129109 |
Ganciclovir
更昔洛韦 |
≥98.0% |
82410-32-0 |
1g,5g,25g,100g |
P125160 |
Penciclovir
喷昔洛韦 |
≥99% |
39809-25-1 |
50mg,250mg,1g |
A125825 |
Atazanavir
阿扎那韦 |
- |
198904-31-3 |
10mg,50mg,250mg,5g |
E181466 |
Entecavir
恩替卡韦 |
98% |
142217-69-4 |
250mg,1g |
D127186 |
Daclatasvir(BMS-790052) |
≥98% |
1009119-64-5 |
10mg,50mg,250mg |
M124903 |
MK-5172 |
98% |
1350514-68-9 |
5mg,10mg |
A126103 |
Asunaprevir
阿那匹韦 |
≥98% |
630420-16-5 |
5mg,10mg,50mg,250mg |
R126586 |
利托那韦
Ritonavir |
≥98% |
155213-67-5 |
10mg,50mg,250mg,500mg |
V127611 |
VX-222 (VCH-222, Lomibuvir) |
≥99% |
1026785-59-0 |
5mg,10mg,50mg |
D125841 |
达芦那韦
Darunavir |
98% |
206361-99-1 |
5mg,10mg,50mg,250mg,1g |
R129802 |
Raltegravir(MK-0518) |
≥97% |
518048-05-0 |
5mg,10mg,50mg,1g |
D127636 |
多替拉韦
Dolutegravir |
≥99% |
1051375-16-6 |
5mg,10mg,50mg |
L299096 |
洛比那韦
Lopinavir |
95% |
192725-17-0 |
10mg,50mg,250mg,1g |
L129320 |
洛比那韦
Lopinavir |
≥99% |
192725-17-0 |
10mg,50mg,100mg,250mg,1g |
抑制新型冠状病毒(2019-nCoV)的内切RNA酶的DTI预测结果
项目号 |
中文名称 |
规格 |
CAS |
包装 |
E135556 |
Efavirenz
依法韦仑 |
≥98%(HPLC) |
154598-52-4 |
10mg,50mg,250mg,1g,5g |
A125825 |
Atazanavir
阿扎那韦 |
- |
198904-31-3 |
10mg,50mg,250mg,5g |
R126586 |
利托那韦
Ritonavir |
≥98% |
155213-67-5 |
10mg,50mg,250mg,500mg |
D127014 |
Danoprevir (ITMN-191) |
≥95% |
850876-88-9 |
2mg,5mg,25mg |
M124903 |
MK-5172 |
98% |
1350514-68-9 |
5mg,10mg |
D127636 |
多替拉韦
Dolutegravir |
≥99% |
1051375-16-6 |
5mg,10mg,50mg |
V127611 |
VX-222 (VCH-222, Lomibuvir) |
≥99% |
1026785-59-0 |
5mg,10mg,50mg |
L299096 |
洛比那韦
Lopinavir |
95% |
192725-17-0 |
10mg,50mg,250mg,1g |
L129320 |
洛比那韦
Lopinavir |
≥99% |
192725-17-0 |
10mg,50mg,100mg,250mg,1g |
D125841 |
达芦那韦
Darunavir |
98% |
206361-99-1 |
5mg,10mg,50mg,250mg,1g |
N137745 |
奈非那韦
Nelfinavir Mesylate |
98% |
159989-65-8 |
10mg,50mg,250mg |
T126775 |
Telaprevir
特拉匹韦 |
≥98% |
402957-28-2 |
5mg,10mg,50mg |
A126552 |
Abacavir
阿巴卡韦 |
≥98.0% |
136470-78-5 |
1g,5g |
R129802 |
Raltegravir(MK-0518) |
≥97% |
518048-05-0 |
5mg,10mg,50mg,1g |
抑制新型冠状病毒(2019-nCoV)的2’-O-核糖 甲基转移酶的DTI预测结果
项目号 |
中文名称 |
规格 |
CAS |
包装 |
E135556 |
Efavirenz
依法韦仑 |
≥98%(HPLC) |
154598-52-4 |
10mg,50mg,250mg,1g,5g |
A125825 |
Atazanavir
阿扎那韦 |
- |
198904-31-3 |
10mg,50mg,250mg,5g |
参考文献
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model.
|
|